Dyadic International (DYAI) risk factors

47 risks, 3 new, 10 dropped, 14 reworded since the prior year. Dyadic is transitioning from a research-driven firm to a commercially focused enterprise commercializing C1 and Dapibus technologies. The company faces extensive regulatory requirements from the FDA, EMA, and other authorities governing pharmaceutical development. Global economic conditions and capital constraints threaten Dyadic's ability to fund operations and execute its strategy.

54 risks. Dyadic's risks are dominated by early-stage biotechnology development uncertainties, reliance on collaborative partnerships, and limited customer concentration.